Literature DB >> 14727180

Origin and spread of the 1278insTATC mutation causing Tay-Sachs disease in Ashkenazi Jews: genetic drift as a robust and parsimonious hypothesis.

Amos Frisch1, Roberto Colombo, Elena Michaelovsky, Mazal Karpati, Boleslaw Goldman, Leah Peleg.   

Abstract

The 1278insTATC is the most prevalent beta-hexosaminidase A ( HEXA) gene mutation causing Tay-Sachs disease (TSD), one of the four lysosomal storage diseases (LSDs) occurring at elevated frequencies among Ashkenazi Jews (AJs). To investigate the genetic history of this mutation in the AJ population, a conserved haplotype (D15S981:175-D15S131:240-D15S1050:284-D15S197:144-D15S188:418) was identified in 1278insTATC chromosomes from 55 unrelated AJ individuals (15 homozygotes and 40 heterozygotes for the TSD mutation), suggesting the occurrence of a common founder. When two methods were used for analysis of linkage disequilibrium (LD) between flanking polymorphic markers and the disease locus and for the study of the decay of LD over time, the estimated age of the insertion was found to be 40+/-12 generations (95% confidence interval: 30-50 generations), so that the most recent common ancestor of the mutation-bearing chromosomes would date to the 8th-9th century. This corresponds with the demographic expansion of AJs in central Europe, following the founding of the Ashkenaz settlement in the early Middle Ages. The results are consistent with the geographic distribution of the main TSD mutation, 1278insTATC being more common in central Europe, and with the coalescent times of mutations causing two other LSDs, Gaucher disease and mucolipidosis type IV. Evidence for the absence of a determinant positive selection (heterozygote advantage) over the mutation is provided by a comparison between the estimated age of 1278insTATC and the probability of the current AJ frequency of the mutant allele as a function of its age, calculated by use of a branching-process model. Therefore, the founder effect in a rapidly expanding population arising from a bottleneck provides a robust parsimonious hypothesis explaining the spread of 1278insTATC-linked TSD in AJ individuals.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14727180     DOI: 10.1007/s00439-003-1072-8

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  48 in total

1.  The mutation rate in the human mtDNA control region.

Authors:  S Sigurğardóttir; A Helgason; J R Gulcher; K Stefansson; P Donnelly
Journal:  Am J Hum Genet       Date:  2000-04-07       Impact factor: 11.025

2.  Assignment of beta-hexosaminidase A alpha-subunit to human chromosomal region 15q23----q24.

Authors:  H Nakai; M G Byers; N J Nowak; T B Shows
Journal:  Cytogenet Cell Genet       Date:  1991

3.  Estimation of age and rate of increase of rare variants.

Authors:  E A Thompson
Journal:  Am J Hum Genet       Date:  1976-09       Impact factor: 11.025

4.  Estimating the age of mutant disease alleles based on linkage disequilibrium.

Authors:  S W Guo; M Xiong
Journal:  Hum Hered       Date:  1997 Nov-Dec       Impact factor: 0.444

5.  A gel electrophoretic assay for detecting the insertion defect in Ashkenazi Jewish carriers of Tay-Sachs disease.

Authors:  S Shore; R Myerowitz
Journal:  Anal Biochem       Date:  1990-04       Impact factor: 3.365

Review 6.  Using linked markers to infer the age of a mutation.

Authors:  B Rannala; G Bertorelle
Journal:  Hum Mutat       Date:  2001-08       Impact factor: 4.878

7.  Mutation of human short tandem repeats.

Authors:  J L Weber; C Wong
Journal:  Hum Mol Genet       Date:  1993-08       Impact factor: 6.150

8.  Age estimate of the N370S mutation causing Gaucher disease in Ashkenazi Jews and European populations: A reappraisal of haplotype data.

Authors:  R Colombo
Journal:  Am J Hum Genet       Date:  2000-02       Impact factor: 11.025

9.  Lower frequency of Gaucher disease carriers among Tay-Sachs disease carriers.

Authors:  L Peleg; A Frisch; B Goldman; M Karpaty; R Narinsky; S Bronstein; M Frydman
Journal:  Eur J Hum Genet       Date:  1998 Mar-Apr       Impact factor: 4.246

10.  The presence of two different infantile Tay-Sachs disease mutations in a Cajun population.

Authors:  G A McDowell; E H Mules; P Fabacher; E Shapira; M G Blitzer
Journal:  Am J Hum Genet       Date:  1992-11       Impact factor: 11.025

View more
  6 in total

1.  A population-genetic test of founder effects and implications for Ashkenazi Jewish diseases.

Authors:  Montgomery Slatkin
Journal:  Am J Hum Genet       Date:  2004-06-18       Impact factor: 11.025

2.  Tay-Sachs disease preconception screening in Australia: self-knowledge of being an Ashkenazi Jew predicts carrier state better than does ancestral origin, although there is an increased risk for c.1421 + 1G > C mutation in individuals with South African heritage.

Authors:  Raelia Lew; Leslie Burnett; Anné Proos
Journal:  J Community Genet       Date:  2011-07-15

Review 3.  Therapeutic Strategies For Tay-Sachs Disease.

Authors:  Jaqueline A Picache; Wei Zheng; Catherine Z Chen
Journal:  Front Pharmacol       Date:  2022-07-05       Impact factor: 5.988

4.  The origin of Eastern European Jews revealed by autosomal, sex chromosomal and mtDNA polymorphisms.

Authors:  Avshalom Zoossmann-Diskin
Journal:  Biol Direct       Date:  2010-10-06       Impact factor: 4.540

5.  A founder deletion in the TRPM1 gene associated with congenital stationary night blindness and myopia is highly prevalent in Ashkenazi Jews.

Authors:  Yoel Hirsch; David A Zeevi; Byron L Lam; Sholem Y Scher; Rachel Bringer; Bitya Cherki; Cadina C Cohen; Hagit Muallem; John Pei-Wen Chiang; Madhulatha Pantrangi; Josef Ekstein; Martin M Johansson
Journal:  Hum Genome Var       Date:  2019-09-12

6.  Efficient and precise generation of Tay-Sachs disease model in rabbit by prime editing system.

Authors:  Yuqiang Qian; Ding Zhao; Tingting Sui; Mao Chen; Zhiquan Liu; Hongmei Liu; Tao Zhang; Siyu Chen; Liangxue Lai; Zhanjun Li
Journal:  Cell Discov       Date:  2021-07-06       Impact factor: 10.849

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.